The global anti-cancer drug market is expected to grow on account of increasing multiple cancer incidences, especially in developed economies. Anti-cancer drug market revenues are expected to increase by 50% in the next five years owing to favorable regulatory scenarios mainly in the U.S. As per the American Cancer Society, number of deaths worldwide in 2012 was 8.2 billion and the number is expected to increase over the forecast period.
Globally, lung cancer is the most common type observed among men. However, in developed regions mainly North America and Europe, prostate is most common among the masculine gender. Breast is the most common type noticed among women in both developed as well as developing economies
The oncology market depends heavily on research and development. Pharmaceutical organizations are concentrating on producing new medicines in order to meet consumer needs. Drug approval from regional regulatory bodies is an important growth factor and therefore support from the regional government bodies and non-profit organizations is expected to drive global anti-cancer drug market demand over the forecast period.
Media is also playing an essential role in spreading awareness about the disease and related drugs. Rise in consumer awareness on availability of new medicines through media are expected to boost the global oncology drug market. Oncology medicine development depends on huge investments for research and development.
High treatment costs and strict government regulations are expected to restrain the global anti-cancer drug market in the future. Pharmaceutical organizations face challenges in recovering the huge cost involved in new product development. These drugs possess a threat of side effects which are expected to hamper overall product demand in the coming years.
Global market is segmented on the basis of treatment type. These treatment segments include chemotherapy, immunotherapy, surgery, radiation therapy, stem cell transplant and hormone therapy. These treatment segments depend upon the cancer type.
North America was the largest market for global oncology drugs owing to developed healthcare industry, government initiatives to increase consumer awareness and advancement in new medicine development. US anti-cancer drug market observed a CAGR of around 6.5% over the period of 2008-2013 and is expected to grow at a CAGR of approximately 29% over the forecast period.
FDA (Food and drug administration) is a federal agency in U.S., responsible for protecting and promoting public health. In 2013, 15 new molecular entities were approved by FDA out of which seven were for cancer. Such favorable regulatory framework is expected to boost overall product demand in the future.
The regional market demand was followed by Europe on account of increasing cancer-related case in the region resulting into deaths. Emerging economies in Asia mainly China, India, Japan, and South Korea are expected to show a steady growth rate in oncology drugs on account of increase in cancer incidence, rise in tobacco consumption, and growing population.
China and India are expected to offer good opportunities on account of improvement in healthcare infrastructure. In Africa, the industry is expected to drive at lower rate on account of lack of healthcare infrastructure, expensive medical services, and lack of consumer awareness.
Central & South America is expected to drive at stable rates on account of costly medicines coupled with minimal awareness initiatives by regional government. The global market is also expected to have legal conflicts arising on account of patents which in turn are expected to negatively impact the overall anti-cancer drug industry.
Key companies producing medicines are Merck, Bristol-Myers Squibb, Bayer, GlaxoSmithKline, Novartis, Sanofi, and Pfizer. Other producers include Amgen, Celgene Corporation, Ariad Pharmaceuticals, Eli Lilly, Hoffmann-La Roche Ltd, AstraZeneca, Boehringer Ingelheim GmbH and Teva Pharmaceuticals.
Top-selling disease-related drugs include Avastin, Rituxan, Herceptin, and Alimta. Patent expiration of these top-selling drugs in the near future is expected to boost the substitute’s growth by 2020. Some of the trends observed are frequent mergers and acquisitions.
These mergers and acquisitions help in expanding technical expertise of multinationals by acquiring smaller firms. On November 23, 2015, Pfizer and Allergan agreed to merge making the largest pharmaceutical deal ever. The agreement is expected to finalize in the second half of 2016.
On April 07, 2014, India based Sun pharmaceutical acquired Ranbaxy making it the fifth-largest pharmaceutical company in the world. Anti-cancer medicines are extremely expensive in nature. Therefore, manufacturers are looking forward to receiving subsidization from the local government in order to cover up the cost involved in new medicine development and supply high-quality products to patients.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.